Search - tctmd.com

Displaying 881 - 900 of 4573

Sort: Relevancy | Date

Presentation TCT 2015

Device and Clinical Program Highlights: Firehawk

Presenter: Pieter C. Smits, Philip M. Urban, Bo Xu

October 12, 2015

Presentation TCT 2015

Why Contemporary Durable Polymers Are Not Good Enough. Do Any of the Current Bioabsorbable Polymers Make the Grade?

Presenter: Pieter C. Smits, Philip M. Urban, Renu Virmani

October 12, 2015

Presentation TCT 2015

Stentys Self-Expanding Stent With a Durable Polymer Eluting Sirolimus: Extended 2-Year Clinical and OCT Results From APPOSITION IV

Presenter: Fernando Alfonso, Juan F. Granada, Robert-Jan van Geuns

October 12, 2015

Presentation TCT 2015

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease - Two-Year Outcomes

Presenter: Ioanna Kosmidou, Bernard R. Chevalier

October 12, 2015

Presentation TCT 2015

A New Durable-PolymerBased Cobalt Chromium Stent: Rationale for and Design Characteristics of the BioNIR Stent and Clinical Development Program

Presenter: Fernando Alfonso, Juan F. Granada, Pieter C. Smits

October 12, 2015

Presentation TCT 2015

Microengineered Grooved Stent Surfaces and Beyond: Technology Description and Preliminary Data

Presenter: Fernando Alfonso, Juan F. Granada

October 12, 2015

Presentation TCT 2015

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Ioanna Kosmidou, Run-Lin Gao

October 12, 2015

Presentation TCT 2015

Debate: Can Todays Metallic Stent Platforms, Delivery Systems, and Durable Polymers Be Meaningfully Improved? No, the Bench, Experimental, and Clinical Results Are So Good, We Probably Have Reached a Therapeutic Plateau!

Presenter: Fernando Alfonso, Juan F. Granada, Lisette Okkels Jensen

October 12, 2015

Presentation TCT 2015

Debate: Can Todays Metallic Stent Platforms, Delivery Systems, and Durable Polymers Be Meaningfully Improved? Yes, Made Thinner and More Flexible, With Optimally Designed Platforms and Enhanced Polymers There Is Still Room for Improvement!

Presenter: Fernando Alfonso, Juan F. Granada, Elazer R. Edelman

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Ioanna Kosmidou, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

Case 4: Dedicated Stent for Left Main PCI

Presenter: Francesco Burzotta, Marie-Claude Morice, Seung-Jung Park, Corrado Tamburino

October 12, 2015

Presentation TCT 2015

The TRYTON PIVOTAL: Randomized Trial and Confirmatory Study: Dedicated Bifurcation Stent in Coronary Bifurcation Involving Large Side Branches

Presenter: Spencer B. King III, Jagat Narula, Philippe Généreux

October 12, 2015

Presentation TCT 2015

CENTURY II: A Prospective Randomized Trial of a Bioabsorbable-Polymer Biolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Two-Year Outcomes

Presenter: Spencer B. King III, Jagat Narula, Shigeru Saito

October 12, 2015

Presentation TCT 2015

Case 2: When I Need 2 Stents, I Prefer TAP

Presenter: Francesco Burzotta, Marie-Claude Morice, Seung-Jung Park, Corrado Tamburino

October 12, 2015

Presentation TCT 2015

DAPT: A Prospective, Double-blind, Placebo-controlled Randomized Trial of 1-year Versus 2.5 Years of Dual Anti-platelet Therapy (Everolimus-Eluting Stent-Treated Subset)

Presenter: Spencer B. King III, Jagat Narula, James B. Hermiller Jr

October 12, 2015

Presentation TCT 2015

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Run-Lin Gao, Gregg W. Stone, Ron Waksman, Run-Lin Gao

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Gregg W. Stone, Ron Waksman, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

Aspirin and ADP Antagonists Before and After Coronary Stent Implantation

Presenter: Paul A. Gurbel, Dmitriy N. Feldman

October 12, 2015

Presentation TCT 2015

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Bernard Chevalier

October 12, 2015

News Conference News TCT 2015

Very Late Stent Thrombosis Remains an Important Clinical Target

October 12, 2015

Advertisement

Device and Clinical Program Highlights: Firehawk

Why Contemporary Durable Polymers Are Not Good Enough. Do Any of the Current Bioabsorbable Polymers Make the Grade?

Stentys Self-Expanding Stent With a Durable Polymer Eluting Sirolimus: Extended 2-Year Clinical and OCT Results From APPOSITION IV

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease - Two-Year Outcomes

A New Durable-PolymerBased Cobalt Chromium Stent: Rationale for and Design Characteristics of the BioNIR Stent and Clinical Development Program

Microengineered Grooved Stent Surfaces and Beyond: Technology Description and Preliminary Data

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Debate: Can Todays Metallic Stent Platforms, Delivery Systems, and Durable Polymers Be Meaningfully Improved? No, the Bench, Experimental, and Clinical Results Are So Good, We Probably Have Reached a Therapeutic Plateau!

Debate: Can Todays Metallic Stent Platforms, Delivery Systems, and Durable Polymers Be Meaningfully Improved? Yes, Made Thinner and More Flexible, With Optimally Designed Platforms and Enhanced Polymers There Is Still Room for Improvement!

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Case 4: Dedicated Stent for Left Main PCI

The TRYTON PIVOTAL: Randomized Trial and Confirmatory Study: Dedicated Bifurcation Stent in Coronary Bifurcation Involving Large Side Branches

CENTURY II: A Prospective Randomized Trial of a Bioabsorbable-Polymer Biolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Two-Year Outcomes

Case 2: When I Need 2 Stents, I Prefer TAP

DAPT: A Prospective, Double-blind, Placebo-controlled Randomized Trial of 1-year Versus 2.5 Years of Dual Anti-platelet Therapy (Everolimus-Eluting Stent-Treated Subset)

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Aspirin and ADP Antagonists Before and After Coronary Stent Implantation

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Very Late Stent Thrombosis Remains an Important Clinical Target

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content